Related Experiment Video
Updated: Sep 4, 2025
07:55
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.0K
Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
Nicholas A Ullman1, Paul R Burchard1, Richard F Dunne1
1University of Rochester Medical Center, Rochester, NY.
Summary
Pancreatic cancer (PDAC) has poor survival rates, and immunotherapy has failed to improve outcomes. This review explores PDAC
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) presents a significant challenge due to rising incidence and poor 5-year survival rates.
- Despite successes in other cancers, immunotherapy has yielded disappointing results in PDAC treatment.
- Preclinical promise in PDAC immunotherapy has not translated effectively into clinical benefits.
Purpose of the Study:
- To summarize the immunosuppressive mechanisms within the pancreatic ductal adenocarcinoma tumor microenvironment.
- To provide an updated review of clinical trials investigating immunotherapy for PDAC.
Main Methods:
- Review of preclinical data on PDAC immunosuppression.
- Analysis of completed and ongoing clinical trials for PDAC immunotherapy.
Main Results:
- PDAC possesses a complex immunosuppressive tumor microenvironment hindering effective anti-tumor immune responses.
- Clinical translation of immunotherapy strategies for PDAC has faced significant challenges.
Conclusions:
- Understanding PDAC's immunosuppressive microenvironment is crucial for developing effective immunotherapies.
- Further research and novel strategies are needed to overcome clinical challenges and improve PDAC treatment outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
01:30Cancer Vaccines
502
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
502